BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 33032924)

  • 21. Comparison of Recurrence Between Pancreatic and Duodenal Neuroendocrine Neoplasms After Curative Resection: A Single-Institution Analysis.
    Masui T; Sato A; Nakano K; Uchida Y; Yogo A; Anazawa T; Nagai K; Kawaguchi Y; Takaori K; Uemoto S
    Ann Surg Oncol; 2018 Feb; 25(2):528-534. PubMed ID: 29164413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.
    Chiramel J; Almond R; Slagter A; Khan A; Wang X; Lim KHJ; Frizziero M; Chakrabarty B; Minicozzi A; Lamarca A; Mansoor W; Hubner RA; Valle JW; McNamara MG
    World J Clin Oncol; 2020 Apr; 11(4):205-216. PubMed ID: 32355642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRI-based nomogram estimates the risk of recurrence of primary nonmetastatic pancreatic neuroendocrine tumors after curative resection.
    Sun HT; Zhang SL; Liu K; Zhou JJ; Wang XX; Shen TT; Song XH; Guo YL; Wang XL
    J Magn Reson Imaging; 2019 Aug; 50(2):397-409. PubMed ID: 30589158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis.
    Gao H; Wang W; Xu H; Wu C; Jin W; Zhang S; Xu J; Ni Q; Yu X; Liu L
    Pancreatology; 2019 Apr; 19(3):472-477. PubMed ID: 30850220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early-Onset Pancreatic Neuroendocrine Tumors: Clinical Presentation, Pathology Features, and Oncological Outcomes.
    Pulvirenti A; Hauser HF; Fiedler LM; McIntyre CA; Le T; Reidy-Lagunes DL; Soares KC; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Raj N; Wei AC
    Ann Surg; 2024 Jan; 279(1):125-131. PubMed ID: 37325926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infiltrative Growth Predicts the Risk of Recurrence After Surgery in Well-Differentiated Non-Functioning Pancreatic Neuroendocrine Tumors.
    Schiavo Lena M; Partelli S; Andreasi V; Muffatti F; Redegalli M; Brunetto E; Maghini B; Falke M; Cangi MG; Perren A; Falconi M; Doglioni C
    Endocr Pathol; 2023 Mar; 34(1):142-155. PubMed ID: 36564582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients.
    Souche R; Coignac A; Dupuy M; Bertrand M; Raingeart I; Guiu B; Herrero A; Panaro F; Obled S; Portales F; Riviere B; Ramos J; Borie F; Quenet F; Colombo PE; Prudhomme M; Assenat E; Fabre JM; ;
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):286-294. PubMed ID: 31543336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of isolated recurrence after surgery for pancreatic adenocarcinoma.
    Kim YI; Song KB; Lee YJ; Park KM; Hwang DW; Lee JH; Shin SH; Kwon JW; Ro JS; Kim SC
    Br J Surg; 2019 Jun; 106(7):898-909. PubMed ID: 31162655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
    Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
    Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
    Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
    Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms.
    Andreasi V; Muffatti F; Guarneri G; Falconi M; Partelli S
    Curr Treat Options Oncol; 2020 Apr; 21(6):48. PubMed ID: 32350693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas.
    Gharios J; Hain E; Dohan A; Prat F; Terris B; Bertherat J; Coriat R; Dousset B; Gaujoux S
    Best Pract Res Clin Endocrinol Metab; 2019 Oct; 33(5):101294. PubMed ID: 31351817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.
    Wei IH; Harmon CM; Arcerito M; Cheng DF; Minter RM; Simeone DM
    Ann Surg; 2014 Dec; 260(6):1088-94. PubMed ID: 25389924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
    Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
    Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preoperative acute pancreatitis and hyperenzymemia are associated with poor prognosis in patients with nonfunctional pancreatic neuroendocrine tumors.
    Song H; Tan Q; Yuan Y; Liu X; Chen Y; Wang X
    J Surg Oncol; 2023 Jun; 127(7):1135-1142. PubMed ID: 36912877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.